# To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.

> **NCT03123653** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 118 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Peg IFN 2b

## Key facts

- **NCT ID:** NCT03123653
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-17
- **Primary completion:** 2019-09-17
- **Final completion:** 2020-09-17
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123653, "To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03123653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*